341 related articles for article (PubMed ID: 26208959)
1. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.
Liu E; Schmidt ME; Margolin R; Sperling R; Koeppe R; Mason NS; Klunk WE; Mathis CA; Salloway S; Fox NC; Hill DL; Les AS; Collins P; Gregg KM; Di J; Lu Y; Tudor IC; Wyman BT; Booth K; Broome S; Yuen E; Grundman M; Brashear HR;
Neurology; 2015 Aug; 85(8):692-700. PubMed ID: 26208959
[TBL] [Abstract][Full Text] [Related]
2. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; Barakos J; Okello AA; Rodriguez Martinez de Liano S; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M
Lancet Neurol; 2010 Apr; 9(4):363-72. PubMed ID: 20189881
[TBL] [Abstract][Full Text] [Related]
3. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S; Sperling R; Fox NC; Blennow K; Klunk W; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Ferris S; Reichert M; Ketter N; Nejadnik B; Guenzler V; Miloslavsky M; Wang D; Lu Y; Lull J; Tudor IC; Liu E; Grundman M; Yuen E; Black R; Brashear HR;
N Engl J Med; 2014 Jan; 370(4):322-33. PubMed ID: 24450891
[TBL] [Abstract][Full Text] [Related]
4. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
[TBL] [Abstract][Full Text] [Related]
5. Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.
Russu A; Samtani MN; Xu S; Adedokun OJ; Lu M; Ito K; Corrigan B; Raje S; Liu E; Brashear HR; Styren S; Hu C
J Alzheimers Dis; 2016 May; 53(2):535-46. PubMed ID: 27163805
[TBL] [Abstract][Full Text] [Related]
6. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.
Drzezga A; Grimmer T; Henriksen G; Mühlau M; Perneczky R; Miederer I; Praus C; Sorg C; Wohlschläger A; Riemenschneider M; Wester HJ; Foerstl H; Schwaiger M; Kurz A
Neurology; 2009 Apr; 72(17):1487-94. PubMed ID: 19339712
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal head-to-head comparison of
Chen CD; McCullough A; Gordon B; Joseph-Mathurin N; Flores S; McKay NS; Hobbs DA; Hornbeck R; Fagan AM; Cruchaga C; Goate AM; Perrin RJ; Wang G; Li Y; Shi X; Xiong C; Pontecorvo MJ; Klein G; Su Y; Klunk WE; Jack C; Koeppe R; Snider BJ; Berman SB; Roberson ED; Brosch J; Surti G; Jiménez-Velázquez IZ; Galasko D; Honig LS; Brooks WS; Clarnette R; Wallon D; Dubois B; Pariente J; Pasquier F; Sanchez-Valle R; Shcherbinin S; Higgins I; Tunali I; Masters CL; van Dyck CH; Masellis M; Hsiung R; Gauthier S; Salloway S; Clifford DB; Mills S; Supnet-Bell C; McDade E; Bateman RJ; Benzinger TLS;
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2669-2682. PubMed ID: 37017737
[TBL] [Abstract][Full Text] [Related]
8. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
Liu E; Wang D; Sperling R; Salloway S; Fox NC; Blennow K; Scheltens P; Schmidt ME; Streffer J; Novak G; Einstein S; Booth K; Ketter N; Brashear HR;
Neurology; 2018 Mar; 90(10):e877-e886. PubMed ID: 29429971
[TBL] [Abstract][Full Text] [Related]
9. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
Brody M; Liu E; Di J; Lu M; Margolin RA; Werth JL; Booth K; Shadman A; Brashear HR; Novak G
J Alzheimers Dis; 2016 Oct; 54(4):1509-1519. PubMed ID: 27589523
[TBL] [Abstract][Full Text] [Related]
10. Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis.
Zeydan B; Lowe VJ; Reichard RR; Przybelski SA; Lesnick TG; Schwarz CG; Senjem ML; Gunter JL; Parisi JE; Machulda MM; Vemuri P; Mielke MM; Knopman DS; Petersen RC; Jack CR; Kantarci OH; Kantarci K
Ann Neurol; 2020 Apr; 87(4):556-567. PubMed ID: 31970802
[TBL] [Abstract][Full Text] [Related]
11. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
[TBL] [Abstract][Full Text] [Related]
12. Cerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease.
Yates PA; Sirisriro R; Villemagne VL; Farquharson S; Masters CL; Rowe CC;
Neurology; 2011 Jul; 77(1):48-54. PubMed ID: 21700585
[TBL] [Abstract][Full Text] [Related]
13. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia.
Ossenkoppele R; van der Flier WM; Zwan MD; Adriaanse SF; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van Berckel BN
Neurology; 2013 Jan; 80(4):359-65. PubMed ID: 23255822
[TBL] [Abstract][Full Text] [Related]
14. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.
Chen K; Roontiva A; Thiyyagura P; Lee W; Liu X; Ayutyanont N; Protas H; Luo JL; Bauer R; Reschke C; Bandy D; Koeppe RA; Fleisher AS; Caselli RJ; Landau S; Jagust WJ; Weiner MW; Reiman EM;
J Nucl Med; 2015 Apr; 56(4):560-6. PubMed ID: 25745091
[TBL] [Abstract][Full Text] [Related]
15. Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.
Novak G; Fox N; Clegg S; Nielsen C; Einstein S; Lu Y; Tudor IC; Gregg K; Di J; Collins P; Wyman BT; Yuen E; Grundman M; Brashear HR; Liu E
J Alzheimers Dis; 2016; 49(4):1123-34. PubMed ID: 26639957
[TBL] [Abstract][Full Text] [Related]
16. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.
Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Iida H; Kishimoto T; Nagatsuka K
Neuroimage Clin; 2017; 13():209-214. PubMed ID: 28003959
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
Salloway S; Sperling R; Gilman S; Fox NC; Blennow K; Raskind M; Sabbagh M; Honig LS; Doody R; van Dyck CH; Mulnard R; Barakos J; Gregg KM; Liu E; Lieberburg I; Schenk D; Black R; Grundman M;
Neurology; 2009 Dec; 73(24):2061-70. PubMed ID: 19923550
[TBL] [Abstract][Full Text] [Related]
18. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
[TBL] [Abstract][Full Text] [Related]
19. β-Amyloid Load on PET Along the Continuum of Dementia With Lewy Bodies.
Diaz-Galvan P; Przybelski SA; Lesnick TG; Schwarz CG; Senjem ML; Gunter JL; Jack CR; Min HP; Jain M; Miyagawa T; Forsberg LK; Fields JA; Savica R; Graff-Radford J; Jones DT; Botha H; St Louis EK; Knopman DS; Ramanan VK; Ross O; Graff-Radford N; Day GS; Dickson DW; Ferman TJ; Petersen RC; Lowe VJ; Boeve BF; Kantarci K
Neurology; 2023 Jul; 101(2):e178-e188. PubMed ID: 37202168
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
